Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
12
×
san francisco blog main
12
×
boston blog main
boston top stories
national top stories
san francisco top stories
biotech
new york blog main
deals
national
new york top stories
gene editing
gene therapy
san diego blog main
san diego top stories
boston
boulder/denver blog main
boulder/denver top stories
crispr
detroit blog main
detroit top stories
hemophilia
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
sangamo therapeutics
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
vc
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
cancer
celgene
clinical trials
What
gene
12
×
therapy
bio
editing
medicine
roundup
crispr
drug
medicines
race
aren’t
cas
cutting
edge
editas
genetic
help
human
long
market
moves
patients
prices
sangamo
science
therapeutics
treatment
abbvie
advanced
alliance
alnylam’s
alzheimer’s
approval
beam
becker
benefit
bff
billions
biotech
cancer
Language
unset
Current search:
" national blog main "
×
" san francisco blog main "
×
gene
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M